Ivermectin, Fenbendazole and Mebendazole for Stage 4 Prostate Cancer: A Case Series of 37 Patients (June 2026 Update)
Integrative Oncology | Repurposed Drug Case Series | Updated june 2026
By One Day MD • Originally published Aug 9, 2025 • Updated May 2026 • Reading time ~24 min
| Editorial note: This article compiles anecdotal case reports, social media testimonials, and a small number of peer-reviewed case studies. It is for educational and research purposes only, is not medical advice, and has not been evaluated by the FDA. Nothing here should be used to start, stop, or replace conventional cancer treatment without consulting an oncology team. |
Abstract
Background: The global burden of advanced prostate cancer remains a significant challenge, particularly in low- and middle-income countries where access to effective therapies is limited. Repurposing existing antiparasitic drugs — ivermectin, fenbendazole, and mebendazole — has drawn attention following anecdotal reports of anti-cancer effects.
Objective: To compile and systematically present case reports and preliminary data on the use of ivermectin and benzimidazoles in patients with Stage 4 prostate cancer, providing a foundation for further scientific investigation.
Methods: Case reports were collected from social media (primarily X/Twitter), patient forums, Substack publications, and published case reports, organized by primary drug emphasis and supplemented with reported outcomes such as PSA change, imaging findings, and quality-of-life measures.
Results: Thirty-seven case reports were compiled spanning September 2022 through May 2026. Reported outcomes include substantial PSA reductions (in some cases >99%), regression of bone and lymph node metastases on imaging, and improved mobility and quality of life. One case was an independently published peer-reviewed case report (Case Reports in Oncology, 2025).
Conclusion: These anecdotal reports suggest a possible anti-cancer signal for ivermectin and benzimidazoles in advanced prostate cancer, warranting controlled clinical investigation. Patients should consult oncology specialists before considering these agents.
Keywords: ivermectin, fenbendazole, mebendazole, repurposed drugs, advanced prostate cancer, Stage 4 prostate cancer, case reports, integrative oncology
| Contents |
|
1. Introduction 2. Case Presentations (37 Cases) 3. Discussion 4. Conclusion 5. FAQ 6. References |
1. Introduction
Access to effective, cancer-specific therapies remains limited, particularly in low- and middle-income countries, where cancer survival rates lag behind high-income settings due to inadequate funding and infrastructure. This has driven interest in repurposing existing, off-patent drugs as more affordable alternatives.
Unlike localized prostate cancer, for which the five-year survival rate approaches 100%, the prognosis for advanced disease depends heavily on the site of spread. According to the National Cancer Institute's SEER database, regional metastasis carries a five-year survival rate near 100%, while distant metastasis — cancer that has spread beyond the pelvis — drops to approximately 37%.
Standard-of-care therapies for advanced prostate cancer include androgen deprivation therapy (ADT), chemotherapy (e.g., docetaxel), androgen receptor pathway inhibitors (enzalutamide, abiraterone), and radiopharmaceuticals (e.g., Lu-177-PSMA-617). Leuprolide and similar ADT injections can demineralize bone at rates up to 11% per year, and resistance mechanisms such as the AR-V7 splice variant limit the durability of androgen-pathway therapies. For patients whose disease becomes resistant or who exhaust standard options, treatment choices narrow considerably.
Ivermectin and the benzimidazoles fenbendazole (FBZ) and mebendazole have drawn growing off-label interest as either standalone or adjunctive therapy. Interest accelerated following widespread anecdotal "cancer success story" reports — by 2026, compilations across cancer types had grown to more than 600 documented case reports spanning over 20 cancer subtypes. None of this is indexed in peer-reviewed literature databases such as PubMed, and the evidence remains overwhelmingly anecdotal.
Note: Given the complexity of cancer treatment, patients should consult a specialized oncology team to determine the most appropriate course of action for their specific diagnosis.
2. Case Presentations
The 37 cases below are organized chronologically, most recent first, and are grouped by primary drug emphasis: fenbendazole-focused, ivermectin-focused, or combination protocols (typically ivermectin + fenbendazole, often with hormone therapy or adjunct supplements). Outcomes are reported as shared by patients, family members, or treating physicians and have not been independently verified.The primary source was the OneDayMD case compilation available at https://onedaymd.substack.com/p/ivermectin-fenbendazole-and-mebendazole-3c9 (May 2026 update), comprising 37 case reports numbered sequentially. Sources within this compilation included: (i) peer-reviewed publications (including a case series published in Case Reports in Oncology, May 2025, and a survey study by Hulscher et al., 2026); (ii) posts on X.com (formerly Twitter) by Dr. William Makis (previously, a Canadian physician and now based in Florida); (iii) Substack publications; and (iv) personal patient testimonials shared via direct communication with the compiler.
| CASE 37 · 2026 · Sweden · 75-year-old man, Gleason 9, bone metastases |
|
Reported by Dr. William Makis (X.com, May 2026). Started November 2025: ivermectin 1 mg/kg/day, fenbendazole 1,500 mg/day, plus hormone therapy (bicalutamide, enzalutamide). Results after 5 months: PSA 0.12. Follow-up X-ray and scintigraphy reportedly showed resolution of bone, pelvic, and lung metastases to scar tissue only, with marked reduction of the primary prostate tumor. |
| CASE 36 · 2026 · Ohio, USA · 63-year-old man |
|
Reported by Dr. William Makis (X.com, April 2026). Started July 2025: ivermectin, fenbendazole, MCP, CBD oil. Results after 6 months: Tumor shrinkage reported; chemotherapy avoided. |
| CASE 35 · 2026 · USA (California physician's family member) |
|
Reported by Dr. William Makis (X.com, March 2026) — testimonial from a California physician regarding a family member with Stage 4 prostate cancer told no treatment options remained. Outcome details limited; original posting subsequently removed from X.com (see note below). |
| CASE 34 · 2026 · Connecticut, USA · 53-year-old man |
|
Reported by Dr. William Makis (X.com, March 2026). Companion testimonial to Case 33 (Connecticut). Detailed outcome data not independently available following link removal. |
Editorial note: Most of Dr. William Makis's original X.com links cited in Cases 34–35 are now broken or inaccessible, reportedly related to legal or regulatory proceedings involving Canadian authorities; the precise cause is not publicly confirmed. The majority of his case reports are now mirrored and actively updated on his Substack, COVID Intel by William Makis (makisw.substack.com).
| CASE 33 · 2026 · Connecticut, USA · 53-year-old man |
|
Reported by Dr. William Makis (X.com, March 2026). Patient exercised "Right to Try" provisions for repurposed drugs. Results after 5–6 months: PSA reportedly dropped 99.9%; ~50% tumor shrinkage. Treating oncologist described the patient as "responding well," reportedly unaware the patient was using ivermectin or fenbendazole. |
| CASE 32 · 2026 · Saudi Arabia · 80-year-old man, bone metastases |
|
Reported by Dr. William Makis (X.com, February 2026). Started September 2025: ivermectin and mebendazole, fenbendazole added subsequently. Results over 4 months: PSA dropped from 1,277 to 8.69. Family reported the local physician was "very surprised" by the degree of improvement. |
| CASE 31 · 2025 · Texas, USA · 66-year-old man, extensive bone metastases |
|
Reported by Dr. William Makis (X.com, November 2025). Started April 28, 2025: ivermectin 70 mg/day, fenbendazole 1,554 mg/day. No chemotherapy. Results after 4 months: PSA 531 → 0.19; alkaline phosphatase (ALP) 1,709 → 53. Treating neurosurgeon reportedly described bone healing as significant and assumed the patient was on chemotherapy. |
| CASE 30 · 2025 · Canada · 69-year-old man, liver metastases |
|
Reported by Dr. William Makis (X.com, October 2025). Started April 7, 2025: ivermectin 1.5 mg/kg/day, fenbendazole 1,500 mg/day. Results after 4 months: Liver metastases reportedly "improved significantly" on imaging; patient reported improved energy, sleep, and overall wellbeing. |
| CASE 29 · 2025 · California, USA · 68-year-old man, vertebral destruction, paraplegia |
|
Reported by Dr. William Makis (X.com, October 2025). Patient reportedly discharged by oncology to hospice care after vertebral collapse left him paraplegic. Started April 22, 2025: ivermectin 1 mg/kg/day, fenbendazole 2,000 mg/day. Results after 5 months: Patient reportedly regained ambulation (from wheelchair to walker); PSA 217 → 0.19; resolution of metastatic bone pain. |
| CASE 28 · 2025 · Australia · 66-year-old man |
|
Reported by Dr. William Makis (X.com, October 2025). PSA at baseline 736. Started late March 2025: ivermectin 1 mg/kg/day, fenbendazole 1,776 mg/day, plus two goserelin (hormone suppression) injections. Results: PSA fell to 15.1; patient became a candidate for TURP and prostate artery embolization (PAE). Urologist reportedly described the treatment response as "profound." |
| CASE 27 · 2025 · North Carolina, USA · 60-year-old man, Gleason 9, bone metastases |
|
Reported by Dr. William Makis (X.com, October 2025). Started early November 2024: ivermectin 108 mg/day, fenbendazole 1,332 mg/day; physician added hormone therapy. Results after 6 months: PSA 196 → 0.16; 50% reduction in metastatic lymph nodes on imaging. |
| CASE 26 · 2025 · Ohio, USA · Hybrid Orthomolecular Protocol (Jeffrey Kramer, retired attorney) |
|
Mr. Jeffrey Kramer of Shelby, Ohio, retired as a plaintiff's civil fraud attorney in 2024 after a diagnosis of metastatic Stage 4 prostate cancer involving the hip bones, lumbar spine, and inguinal lymph nodes. His Cleveland Clinic oncologist advised the disease was incurable but manageable short-term via leuprolide and apalutamide, with leuprolide carrying a bone demineralization risk of up to 11% per year. Mr. Kramer learned of a peer-reviewed protocol — "Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol" — published in the September 2024 Journal of Orthomolecular Medicine by sixteen physicians and researchers, footnoted to 204 studies. U.S./Canadian co-authors he contacted directly could not formally assist due to lack of FDA/clinical-trial approval and licensure risk. Pierrick Martinez of the Association Cancer et Métabolisme (Nîmes, France), the protocol's lead author, provided remote supervision of the 15-week protocol, which included high-dose IV vitamin C and a therapeutic ketogenic diet coordinated with a Cleveland Clinic-affiliated nutritionist. Outcome: Mr. Kramer completed the 15-week protocol on June 5, 2025, with no reported side effects. An FDG-PET scan two weeks later reportedly showed no evidence of active cancer anywhere in the body. Total protocol cost was reported at under $20,000. |
| CASE 25 · 2025 · Washington, USA · 58-year-old man, Gleason 9, bone metastases |
|
Reported by Dr. William Makis (X.com, September 2025). Started early March 2025: ivermectin 1.5 mg/kg/day, fenbendazole 2,000 mg/day (higher than typical starting dose, attributed to disease severity and patient tolerance). Results after 3 months: PSA 23.2 → below 1; metastatic lymph nodes reportedly resolved; bone metastases described as healed over (sclerotic) on imaging. |
| CASE 24 · 2025 · Nevada, USA · 64-year-old man, lung and spine metastases |
|
Reported by Dr. William Makis (X.com, August 2025). Started early February 2025: ivermectin 1.5 mg/kg/day, fenbendazole 1,500 mg/day, CBD oil 100 mg/day. Results after 4 months: PSA 79 → 0.32. |
| CASE 23 · 2025 · New York, USA · 63-year-old man |
|
Reported by Dr. William Makis (X.com, August 2025). Started early February 2025: ivermectin 1.5 mg/kg/day, fenbendazole 1,500 mg/day, plus oncologist-prescribed Orgovyx and Nubeqa. Results after 4 months: PSA 64.9 → <0.1. Family reported oncologist was "very pleased," with planned chemotherapy discussions postponed. |
| CASE 22 · 2025 · Alberta, Canada · Avoided radical prostatectomy and pelvic radiation |
|
Reported by Dr. William Makis (X/Twitter, June 2025). Patient declined offered radical prostatectomy and full pelvic radiation, citing a quoted 50% chance of "normal" function post-procedure. Pursued ivermectin and fenbendazole alongside proton therapy in Seattle, followed by continued ivermectin and fenbendazole with MCT oil for 3 months. Results: PSA fell from a high of 9.0 to 1.7; prostate gland reportedly remained intact with normal reported bodily function. |
| CASE 21 · 2025 · USA · 74-year-old man, liver and lymph node metastases (extended narrative) |
|
Originally diagnosed with prostate cancer in 2019 and treated surgically with an "all clear." Recurrence emerged in 2024: PSA rose from 14 (August) to 51 (mid-August), with PET imaging revealing liver and lymph node metastases, biopsy-confirmed. His oncology center (MD Anderson) characterized the liver as "completely consumed," offering palliative care with a 12–18 month prognosis on a plan of Lupron followed by chemotherapy. After one Lupron injection, the patient began a self-directed fenbendazole regimen in late August 2024 (titrated to 222 mg twice daily, total 444 mg/day) without disclosing this to his oncologist, alongside a ketogenic diet, daily low-dose ivermectin, high-dose IV vitamin C (50–75 g, three times weekly), and monthly water/bone-broth fasts. Timeline of reported outcomes: Early November 2024 — PET scan showed 50% reduction in all tumors; PSA fell from 51 to 2; scheduled chemotherapy was cancelled. January 2025 — additional 50% decrease from the November scan (75% cumulative tumor reduction in five months). May 2025 — no evidence of disease on PET/CT. June 2025 follow-up — additional 30% reduction reported, with lymph node and lung lesions described as fully resolved (80% total reduction). No fenbendazole-attributable adverse effects were reported; the patient monitored liver enzymes independently after two early elevations. |
| CASE 20 · 2025 · PEER-REVIEWED · 75-year-old man, recurrent Stage 4, extensive bone metastases |
|
Published in Case Reports in Oncology (May 2025). Originally diagnosed and treated surgically 10 years prior; recurrence confirmed December 2021 with bone metastases (spine, pelvis, right humeral head) and lymph node involvement. Treatment from December 2021: androgen deprivation therapy (Orgovyx, Erleada) plus Xgeva for bone support, alongside vitamin D/K2/magnesium, melatonin (10–40 mg/day), berberine, curcumin, artemisinin, cimetidine, and fenbendazole (222–444 mg/day, with occasional dose reductions). Reported outcomes: Regression of bone lesions and full resolution of lymph node involvement by December 2022 (1 year). Sustained regression with no new metastatic sites by January 2024 (2 years). PSA undetectable (<0.05 ng/mL) for over 2 years. April 2024 PSMA-PET/CT showed the majority of sclerotic bone lesions with no abnormal radiopharmaceutical uptake. After 26 months, the patient remained in near-complete response on continued fenbendazole plus ADT, with no FBZ-attributable liver enzyme elevation or other adverse effects reported. |
| CASE 19 · 2025 · North Carolina, USA · 77-year-old man, lung and bone metastases |
|
Reported by Dr. William Makis (X/Twitter, June 2025). Started late November 2024: ivermectin 1.5 mg/kg/day, fenbendazole 888 mg/day, CBD oil 50 mg/day, alongside oncologist-directed chemotherapy. Results after 5 months (PET/CT, May 4, 2025): Near-complete resolution of disease — single residual prostate focus (SUVmax 4.8, down from near-total gland involvement); pelvic and periaortic lymph node activity resolved or markedly reduced; only 3 residual skeletal foci remained; resolution of a previously noted pulmonary nodule. |
| CASE 18 · 2025 · Australia · 78-year-old man |
|
Reported by Dr. William Makis (X/Twitter, June 2025). Patient on chemotherapy (docetaxel) and hormone therapy (goserelin) additionally started ivermectin 1 mg/kg/day and fenbendazole 1,000 mg/day. Results after under 2 months: PSA 385 → 1.2; metastatic disease reportedly shrinking on PET/CT. Makis notes that some prostate cancers in his cohort appear resistant to this protocol with no identifiable predictive feature. |
| CASE 17 · 2025 · Washington, USA · 87-year-old man, bone and spine metastases |
|
Reported by Dr. William Makis (X/Twitter, June 2025). Started late March 2025 with severe bone pain and mobility loss: ivermectin 1 mg/kg/day, fenbendazole 1,000 mg/day. Results over 2 months: PSA progression reported by family as 2,093 → 83 → 39, with progressive reduction in leg pain and a transition from walker/cane dependence to unassisted walking. Treating oncologist reportedly described the response as surprising. |
| CASE 16 · 2025 · (Duplicate-pattern testimonial, June 2025) |
|
Shared by Dr. William Makis with overlapping PSA-trend details to Case 17 above (bone/spine metastases, progressive PSA decline, mobility improvement). Retained here for completeness of the original source compilation. |
| CASE 15 · 2025 · Metastatic prostate cancer |
|
Shared by Dr. Peter McCullough (X.com, May 2025): a patient with metastatic prostate cancer reported a PSA decline from 200 to 2 after starting ivermectin. |
| CASE 14 · 2025 · 93-year-old man, hip bone metastasis |
|
Family testimonial (X.com, May 2025): patient reported as cancer-free within 2 months on ivermectin alone (no chemotherapy or radiation), with total drug cost cited at under $80. |
| CASE 13 · Stage 4 prostate cancer (Paul Mann, reported by Dr. Kathleen Ruddy) |
|
Reported by Dr. Kathleen Ruddy: patient diagnosed with Stage 4 prostate cancer shortly after a COVID-19 vaccination series, with disease in 11 bones and a baseline PSA in the 700–800 range. After exhausting standard radiation, chemotherapy, and hormone therapy over nine months with no further options offered, the patient began self-administered ivermectin without informing his treating oncologist. Reported outcome: PSA fell to 1.3 at a two-month follow-up, described by his care team as "biochemical remission" (bone metastases persisted). Gradual improvement in pain and swelling was reported thereafter. |
| CASES 7–12 · February 2025 · Compiled testimonials (Dr. William Makis, X/Twitter) | ||||||||||||
|
| CASE 6 · 2024 · Stage 4, Gleason 9, bone metastases |
|
Patient testimonial (HealthUnlocked, 2024). Diagnosed January 2024 with PSA 143, Gleason 9, bone metastases. Began the Joe Tippens protocol immediately. Results: PSA fell to 26 at two months and to zero by the fourth-month mark, per patient report; treating physician reportedly deemed further imaging unnecessary, though bone radiation was still planned. |
| CASE 5 · December 2024 · British Columbia, Canada · 79-year-old man, lymph node involvement |
|
Reported by Dr. William Makis. Diagnosed late 2022, Gleason 8, peak PSA 19.72; completed 28 radiation treatments; on hormone blockers and abiraterone with no tumor regression. Protocol added: ivermectin 1 mg/kg/day, fenbendazole 444 mg/day, melatonin 120 mg/day, IP6, artemisia. Results at ~4 months: Oncologist-reported shrinkage across the prostate, bladder wall, and lymph nodes; not yet in remission. |
| CASE 4 · November 2024 · Stage 4 |
|
Reported by Dr. William Makis: ivermectin 1 mg/kg and fenbendazole 1,000 mg on a 3-days-on/4-days-off schedule. PSA fell from 1,533 to 968 (37%) in 12 days; abdominal lymph node enlargement reportedly resolved. Fatigue and bone pain were noted as expected with rapid tumor cell death. |
| CASE 3 · November 2024 · Ecuador · Gleason 8 |
|
Reported by Dr. William Makis: intermediate-dose protocol (ivermectin 1 mg/kg/day; fenbendazole 222–444 mg/day) plus ketogenic diet. PSA reportedly fell from 800 to 18 over 3 months. |
| CASE 2 · October 2024 · Aggressive Stage 4 |
|
Reported by Dr. William Makis: PSA reportedly reduced to 0.02 on an ivermectin and fenbendazole protocol, described by the patient's care team as a rapid result. |
| CASE 1 · September 2022 · 55-year-old man ("Adam"), extensive skeletal metastases |
|
Patient narrative shared by spouse. Diagnosed February of the index year with PSA 140, Gleason 9, metastases throughout the skull, facial bones, clavicle, sternum, ribs, spine, and pelvis, with associated pathologic fractures. Treating oncologist reportedly estimated 18 months of life remaining; radiation was not offered, and only six rounds of docetaxel were planned, with hormone/chemotherapy delayed seven weeks. The family began fenbendazole (222 mg starting dose) two weeks post-diagnosis, sourced informally with guidance from a family contact. Long-term outcome data from this account were not specified in the original source. |
3. Discussion
Stage 4 prostate cancer, defined by distant metastases, carries an approximate 37% five-year survival rate under standard-of-care treatment, including ADT, chemotherapy (e.g., docetaxel), and radiopharmaceuticals (e.g., Lu-177-PSMA-617).
The compiled case reports suggest a possible anti-cancer signal for ivermectin and benzimidazoles, almost always used alongside conventional therapy. Proposed mechanisms include inhibition of the WNT-TCF signaling pathway, induction of apoptosis, and chemosensitization or radiosensitization. Reported outcomes include substantial biomarker declines — in several cases, PSA fell by more than 90% — alongside improved quality of life and mobility. These reports remain anecdotal, lacking the rigor of controlled trials, and are subject to self-selection bias, absent control groups, and incomplete or unverifiable follow-up.
Variability in response is notable: some patients (e.g., Cases 18 and 32) responded rapidly within weeks to months, while Dr. Makis has separately reported a subset of prostate cancers that appear fully resistant to the ivermectin/fenbendazole combination with no identifiable predictive feature. Dosing also varies substantially across cases — ivermectin ranging roughly from 70 mg/day to 1.5–2 mg/kg/day, and fenbendazole from 222 mg/day to 2,000 mg/day — underscoring the absence of a standardized protocol. Cost considerations also differ markedly: fenbendazole is estimated at roughly $0.48 per 222 mg dose, versus approximately $450 per pill for mebendazole in the U.S. retail market, a disparity relevant to accessibility in resource-limited settings.
Limitations of this compilation are substantial: lack of randomization or control arms, concurrent conventional therapy in nearly all cases (confounding attribution), reliance on patient- or family-reported outcomes, and the inherent unverifiability of social-media-sourced testimonials, several of which were later partially or fully inaccessible (see Cases 34–35). Risks of drug interactions and toxicity at higher doses, particularly with prolonged use, also require careful clinical evaluation that case reports cannot provide.
4. Conclusion
Fenbendazole, ivermectin, and mebendazole represent candidate adjuncts of interest in advanced prostate cancer, particularly for patients who have exhausted conventional options. Simulation modeling and accumulating real-world reports suggest a potential survival and quality-of-life signal beyond current standard-of-care alone for Stage 4 prostate cancer — but this remains a hypothesis, not an established finding.
The current evidence base rests overwhelmingly on case reports and testimonials, which generate hypotheses but cannot establish causation or efficacy at the standard required for clinical practice. Until controlled trial data are available, patients and clinicians should rely on established, evidence-based therapies, with any off-label use of these agents considered only within structured research settings — including N-of-1 trial designs — under appropriate specialist oversight and informed consent.
Patients and clinicians seeking a deeper understanding are encouraged to review emerging research and consider participation in registered clinical trials. Treatment decisions should always be made in close consultation with a qualified oncology team.
5. Frequently Asked Questions
| Is there clinical trial evidence that ivermectin or fenbendazole treat prostate cancer? |
| No. As of mid-2026, no completed randomized controlled trials in humans have tested ivermectin, fenbendazole, or mebendazole specifically for prostate cancer. The evidence base consists of anecdotal case reports, social media testimonials, a small number of published case reports, and preclinical studies — hypothesis-generating, not confirmatory. |
| Why do case reports show dramatic PSA drops if the drugs are unproven? |
| Nearly all cases in this compilation combined fenbendazole or ivermectin with standard hormone therapy, chemotherapy, or radiotherapy independently capable of producing similar PSA declines. Self-selection bias (successes are shared; failures rarely are), absent controls, and lack of independent verification mean the relative contribution of the repurposed drugs cannot be isolated from these reports. |
| Are ivermectin and fenbendazole safe to combine with prostate cancer hormone therapy? |
| Short-term tolerability reported in these series was generally favorable at the doses used, but rigorous pharmacokinetic and drug-interaction data in cancer patients are lacking. Patients should not start or stop any therapy without discussing it with their treating oncology team, given the risk of undisclosed interactions and of delaying effective standard-of-care treatment. |
| What is the proposed mechanism of action for these drugs in cancer? |
| Proposed mechanisms include ivermectin's inhibition of WNT-TCF signaling and disruption of mitochondrial function and glycolysis, and benzimidazole-induced microtubule destabilization that can trigger apoptosis and potentially chemosensitize or radiosensitize tumor cells. These mechanisms are supported by in vitro and animal data but have not been confirmed to drive clinical outcomes in human prostate cancer. |
Disclaimer: Statements on this website have not been evaluated by the Food and Drug Administration. Content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This work does not constitute medical advice. Patients should consult licensed healthcare providers before initiating any treatment.
Acknowledgments: The authors acknowledge patients and advocates who shared their experiences on public platforms, and researchers including Dr. William Makis for documenting these cases.
6. References
- World Economic Forum. Global cancer funding shortfall, 2024.
- World Health Organization. Global cancer burden growing amidst mounting need for services, 2024.
- Yuan Y, et al. Phase I/II study of ivermectin and balstilimab in metastatic triple-negative breast cancer. J Clin Oncol. 2025; Abstract e13146.
- Melotti A, et al. The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014;6(10):1263–1278.
- Mudassar F, et al. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Neurooncol. 2020;147(2):393–403.
- Zhang L, et al. Mebendazole potentiates radiation therapy in triple-negative breast cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):195–207.
- National Cancer Institute SEER Program. Cancer Stat Facts: Prostate Cancer.
- Case Reports in Oncology. Fenbendazole as an anticancer agent: case series, May 2025.
- AI-modeled simulated randomized controlled trial: Ivermectin, Mebendazole, Metformin, High-Dose Vitamin C, Hyperthermia and More for Stage 4 Prostate Cancer (2025).
- One Day MD. Fenbendazole and Ivermectin for Cancer: Real Stories, Science & Protocols (2025 Comprehensive Guide).
- One Day MD. Ivermectin, Fenbendazole, and Mebendazole for Stage 4 Cancer: 310+ Case Reports Compilation (2026 Edition).
- One Day MD. Fenbendazole and Ivermectin for Prostate Cancer Success Stories (including other stages of prostate cancer), 120+ case reports.
| Where to Source Ivermectin and Mebendazole |
|
The Wellness Company's Ivermectin and Mebendazole Ivermectin and mebendazole, both approved for human use, available in the U.S. Researched and approved by Dr. Peter McCullough.
|
© 2026 One Day MD. This article is for educational purposes only and does not constitute medical advice.
.png)
.png)
Comments
Post a Comment